AZ/Merck’s Lynparza approved by SMC to treat advanced prostate cancer in Scotland
Up to 20% of prostate cancer cases are classified as castration-resistant
Read More
Tag: Scottish Medicines Consortium
AbbVie’s Produodopa approved by SMC to treat Parkinson’s disease patients in Scotland
The progressive neurological disorder affects approximately 12,400 people in Scotland
Read More
SMC recommends Bayer’s cancer treatments for NHS Scotland use
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read More
SMC accepts oral therapy for relapsing multiple sclerosis
Janssen’s Ponvory accepted for use within NHS Scotland for adults RRMS patients
Read More
SMC approves Bavencio for bladder cancer
The treatment was not recommended by NICE for the NHS in England
Read More
SMC approves funding for four new medicines on the NHS
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
Read More
Zytiga, Ajovy among latest SMC decisions
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Read More
Kymriah leads latest round of SMC decisions
MSD’s Keytruda, Pfizer’s Visimpro, AstraZeneca’s Forxiga and Shionogi’s Senshio were also accepted.
Read More
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read More
SMC OK’s four meds for NHS use, including Roche’s Perjeta
The Scottish Medicines Consortium (SMC) has recommended four medicines – including Roche’s breast cancer drug Perjeta – for use on the NHS.
Read More
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
- Oregon and Lantern collaborate to develop drug candidate for various cancer indications
- OneChain’s CAR T trial treats its first cortical T-cell ALL patient
- Johns Hopkins scientists depict molecular pathway to track replication in cancer cells
